[Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 623–33

Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 2022; 10: 623–33—Appendix 2 of this Article has been corrected as of Oct 15, 2025.